All In Biotech

Drug Trial Radar · NCT07519902

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jun 2, 2026

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Dompé Farmaceutici S.p.AIndustry
Sponsor type
Industry
First posted
Apr 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants with PCED. The primary objective is the evaluation of complete epithelial healing after 4 weeks of treatment. The study is comprised of 3 periods: an 8-week initial treatment period (Day 1 to Week 8), an 8-week extension treatment period (Week 9 to Week 16), and a 24-week follow-up period (Week 17 to Week 40).

Conditions

  • Persistent Corneal Epithelial Defect

Interventions

  • CenegerminDrug

    Cenegermin is administered topically.

  • VehicleOther

    Vehicle is administered topically.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of responders achieving complete epithelial healing of the cornea at Week 4 and maintained at Week 8Time frame: At Weeks 4 and 8

Locations

77 sites in 14 countries. Site status is shown where the registry gives one.

  • Azul Vision, INC

    Huntington Beach, California · Recruiting

  • Harvard Eye Associates

    Laguna Hills, California · Recruiting

  • Loma Linda University Adventist Health Sciences Center

    Loma Linda, California · Not yet recruiting

  • UCLA - Jules Stein Eye Institute (JSEI) - Diabetic Eye Dise

    Los Angeles, California · Not yet recruiting

  • California Eye Specialists Medical Group, Inc.

    Redlands, California · Recruiting

  • East Coast Institute for Research - Florida Eye Specialists

    Jacksonville, Florida · Recruiting

  • Bascom Palmer Eye Institute, University of Miami School of Medicine

    Miami, Florida · Recruiting

  • University of South Florida

    Tampa, Florida · Recruiting

  • Massachusetts Eye and Ear

    Boston, Massachusetts · Recruiting

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts · Recruiting

  • University of Michigan Health - Kellogg Eye Center

    Ann Arbor, Michigan · Recruiting

  • Midwest Vision Research Foundation

    Chesterfield, Missouri · Recruiting

  • NYU Langone Eye Center (Ophthalmology)

    New York, New York · Recruiting

  • Duke Eye Center - Ophthalmology

    Durham, North Carolina · Recruiting

  • Vance Thompson Vision - Sioux Falls

    Sioux Falls, South Dakota · Recruiting

  • Houston Eye Associates (HEA)

    Houston, Texas · Recruiting

  • The Eye Institute of Utah

    Salt Lake City, Utah · Recruiting

  • Virginia Eye Consultants

    Norfolk, Virginia · Recruiting

  • Oftar S.R.L.

    Mendoza, Argentina · Not yet recruiting

  • Hospital Italiano de Buenos Aires

    Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina · Not yet recruiting

  • Buenos Aires Macula S.A. - Clinic

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Not yet recruiting

  • Hospital Universitario Austral

    Pilar, Buenos Aires, Argentina · Not yet recruiting

  • Fundacion Zambrano

    Buenos Aires, Buenos Aires F.D., Argentina · Not yet recruiting

  • Centro Oftalmologico Dr Charles SA

    Buenos Aires, Buenos Aires F.D., Argentina · Not yet recruiting

  • Centro Oftalmológico Salud Ocular

    Rio Negro, Río Negro Province, Argentina · Not yet recruiting

  • Vseobecna fakultni nemocnice v Praze - Ocni klinika

    Prague, Praha, Hlavní Mesto, Czechia · Recruiting

  • APHP Hopital Cochin

    Paris, France · Not yet recruiting

  • Fondation Ophtalmologique A. de Rothschild

    Paris, France · Recruiting

  • CHU Saint Etienne, Hôpital Nord

    Saint-Etienne, Auvergne-Rhône-Alpes, France · Recruiting

  • Centre Hospitalier Regional Universitaire (CHRU) Brest

    Brest, Brittany Region, France · Recruiting

  • Centre Hospitalier Régional Universitaire de Tours

    Tours, Indre-et-Loire, France · Not yet recruiting

  • Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK)

    Berlin, Germany · Recruiting

  • Universitaetsklinikum Erlangen - Augenklinik

    Erlangen, Bavaria, Germany · Recruiting

  • Johann Wolfgang Goethe-Universitaet Frankfurt - Klinik fuer Augenheilkunde

    Frankfurt am Main, Hesse, Germany · Recruiting

  • Philipps-University Marburg

    Marburg, Hesse, Germany · Not yet recruiting

  • Universitaetsklinikum Koeln - Zentrum fuer Augenheilkunde

    Cologne, North Rhine-Westphalia, Germany · Not yet recruiting

  • Kliniken der Stadt Koeln

    Cologne, North Rhine-Westphalia, Germany · Not yet recruiting

  • Heinrich-Heine-Universitaet Duesseldorf - Universitaetsklinikum Duesseldorf (UKD)

    Düsseldorf, North Rhine-Westphalia, Germany · Not yet recruiting

  • Universitaetsklinikum des Saarlandes - Augenklinik

    Homburg, Saarland, Germany · Recruiting

  • Semmelweis Egyetem - Ophthalmology

    Budapest, Hungary · Recruiting

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.